Insider transactions and immediate holdings
On February 17, 2026, BridgeBio Pharma director Scott Randal W. completed sales of 10,000 shares of the company's common stock for approximately $754,556. The disposals were executed across multiple trades at prices that ranged from $74.3421 to $75.9261 per share. That same day, Scott exercised stock options to acquire 10,000 shares at an exercise price of $16.75 per share, resulting in a cash value of $167,500 for the option exercise.
Following those transactions, Scott directly holds 11,589 shares of BridgeBio Pharma common stock. He also possesses an indirect stake of 4,000 shares through Thinking Bench Capital LLC.
Share price context
BridgeBio shares were trading at $73.85 at the time of the report, positioned below the stock's 52-week high of $84.94. The company’s equity has appreciated roughly 108% over the past year, reflecting substantial upside over the twelve-month period.
Clinical progress and analyst reaction
BridgeBio recently disclosed positive results from its Phase 3 PROPEL trial of infigratinib for achondroplasia. The trial met its primary endpoint, producing a statistically significant improvement in annualized height velocity versus placebo, with a mean treatment difference of +2.10 cm/year. The company also reported that this constitutes the first randomized achondroplasia trial to show a statistically significant improvement in body proportionality.
Following the PROPEL readout, Raymond James increased its price target on BridgeBio to $89 and maintained an Outperform rating. Barclays initiated coverage with an Overweight rating and set a $80 price target, pointing to the company's diversified late-stage portfolio. InvestingPro data referenced in the report indicates analysts continue to carry a strong buy consensus, with price targets across the analyst group spanning from $80 to $157.
Financing activity
BridgeBio has priced a convertible senior notes offering totaling $550 million. The notes carry a 0.75% interest rate and were priced with a 45% conversion premium. They are initially convertible at a rate equivalent to a conversion price of $110.58 per share.
Near-term calendar and financial outlook
The company is scheduled to report earnings in six days, on February 24. The report notes that BridgeBio is not expected to be profitable this year, a point highlighted alongside the analyst coverage and recent corporate actions.
Takeaways
The combination of insider option exercise and contemporaneous share sales, a positive Phase 3 clinical result, fresh analyst target activity, and a new convertible note issuance places several moving parts on BridgeBio’s near-term agenda. The firm’s market capitalization is stated at $14.3 billion, and the coming earnings release will be an immediate data point for investors assessing the company’s prospects amid ongoing late-stage development and financing activity.